Update shared on 16 Nov 2025
Fair value Increased 5.50%Analysts have raised their fair value estimate for Vital Energy from $20.14 to $21.25 per share. They cited an improved outlook on capital efficiency and sector sentiment as key drivers for the adjustment.
Analyst Commentary
Recent analyst reports offer a range of perspectives on Vital Energy's outlook, reflecting both confidence and caution as the company moves toward a significant corporate transaction and navigates sector trends.
Bullish Takeaways- Bullish analysts point to a considerable price target increase, suggesting an improved intermediate-term oil sentiment and sector-wide optimism, especially as Q3 earnings approach.
- Expectations for enhanced capital efficiency and the firm’s FY26 outlook are seen as key factors that could drive valuation higher.
- Continued M&A activity and a growing emphasis on exploration, international exposure, and secular gas demand streams are perceived as potential growth catalysts.
- The rapid pace of change across the U.S. onshore landscape could benefit companies positioned for adaptability and operational excellence.
- Bearish analysts recently downgraded Vital Energy following news of its pending all-stock acquisition, adjusting price targets sharply downward amidst concerns about growth prospects post acquisition.
- There is caution that, after the deal announcement, the company’s stock may no longer reflect its underlying fundamentals. This could potentially lead to valuation disconnects.
- Uncertainties around future integration, combined with a reevaluation of projected returns, are contributing to a more conservative outlook.
- The shift in analyst ratings and removal of coverage by some research providers highlight a lack of clear visibility into execution risks going forward.
What's in the News
- Crescent Energy entered into a definitive agreement to acquire Vital Energy in an all-stock transaction valued at approximately $3.1 billion, including net debt. Crescent shareholders will own roughly 77% and Vital shareholders about 23% of the combined company on a fully diluted basis (Key Developments).
- The transaction is unanimously approved by both companies' boards and a special committee of independent directors. Current major shareholders representing approximately 29% of Crescent and 20% of Vital support the deal (Key Developments).
- Vital Energy reported unaudited production results for Q3 2025. Average daily oil equivalent sales volumes were 136,158 BOE/d, an increase from 133,339 BOE/d a year ago (Key Developments).
- Because of the merger, Vital Energy’s prior corporate guidance should no longer be relied upon. The company will not provide updates before the closing of the transaction (Key Developments).
- A special shareholders meeting for Vital Energy is scheduled for December 12, 2025 (Key Developments).
Valuation Changes
- The Fair Value Estimate has increased from $20.14 to $21.25 per share.
- The Discount Rate has decreased from 12.32% to 11.21%.
- The Revenue Growth projection has changed from 1.24% to -1.86%.
- The Net Profit Margin has risen slightly from 24.03% to 24.91%.
- The Future P/E ratio has increased from 2.25x to 2.42x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
